Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1996-07-19
1998-03-17
Walsh, Stephen
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 78, 435 772, 435244, 435325, 435375, 435 691, G01N 3353, G01N 33566, C12N 1509
Patent
active
057285349
ABSTRACT:
The invention features screening methods which can be used to identify agents, known as vasoprotective agents, which inhibit vascular smooth muscle cell activation and/or proliferation or enhance vascular endothelial cell activation and/or proliferation or activate estrogen responsive genes in vascular cells. Preferred vasoprotective agents are relatively vasospecific, i.e., their effect on one or more types of vascular cells is more pronounced than their effect on other cell types. Treatment with such vasospecific agents will generally be associated with fewer undesirable side-effects than treatment with estrogen.
The methods of the invention are screening assays in which candidate agents are examined to identify vasoprotective agents. One type of screening assay involves examining the effect of a candidate agent on cell proliferation and/or cell activation. Another type of screening assay involves examining the effect of a candidate agent on the expression of a gene which is responsive to estrogen. Both screening assays involve the use of vascular cells and non-vascular cells. The use of both cell types is important because the cellular milieu is very likely to influence the effect of a candidate agent on cell proliferation, cell activation, and the expression of an given estrogen receptor responsive gene.
REFERENCES:
patent: 5071773 (1991-12-01), Evans et al.
patent: 5512483 (1996-04-01), Mader et al.
patent: 5597693 (1997-01-01), Evans et al.
Kuiper et al. (1996) Proc. Nat'l. Acad. Sci. USA 93:5925-5930.
Karas, Richard M., "Estrogen plays crucial role in preventing CAD Hormone Replacement reduces risk for postmenopausal women" Progress Notes, p. 5, 1996.
Karas et al., "Human Vascular Smooth Muscle Cells Contain Functional Estrogen Receptor" Circulation 89:1943, 1994.
Koike et al., "Differential-display polymerase chain reaction identifies nucleophosmin as an estrogen-regulated gene in human vascular smooth muscle cells" J. of Vascular Surgery, p. 477, 1996.
Mendelsohn et al., "Estrogen and the blood vessel wall" Current Opinion in Cardiology 9:619, 1994.
Sullivan et al., "Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model" J. Clin. Invest. 96:2482, 1995.
Karas Richard H.
Mendelsohn Michael E.
New England Medical Center Hospitals Inc.
Pak Michael D.
Walsh Stephen
LandOfFree
Methods for identifying cardiovascular therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying cardiovascular therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying cardiovascular therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-956500